We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies
News

MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies

MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies
News

MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG and Sigma-Aldrich has announced a collaboration agreement to design, produce and distribute recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD technology.

MorphoSys's AbD Serotec unit will develop and qualify antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. HuCAL GOLD is the powerful phage-display library developed for the in vitro generation of highly specific and fully human antibodies.

The large diversity of the library guarantees fast and successful generation of high-quality antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies.

Sigma-Aldrich will offer the HuCAL-based recombinant research antibodies for use in research applications through its online sales platforms Antibody Explorer™ and Your Favorite Gene Search™.

"We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."

Advertisement